caa a22 4500 445314176 CHVBK 20180317142640.0 cr unu---uuuuu 170323e20110201xx s 000 0 eng 10.1007/s11095-010-0173-z doi (NATIONALLICENCE)springer-10.1007/s11095-010-0173-z Nanoparticles: A Promising Modality in the Treatment of Sarcomas [Elektronische Daten] [Michiro Susa, Lara Milane, Mansoor Amiji, Francis Hornicek, Zhenfeng Duan] ABSTRACT: Improvements in surgical technique, chemotherapy, and radiotherapy have enhanced the prognosis of sarcoma patients, but have since reached a plateau in recent years. Novel approaches have been sought but with limited results. Nanomedicine offers solutions in diverse areas of sarcoma therapy including diagnosis and treatment. Several varieties of nanoparticles, including multifunctional nanoparticles, are available that localize the biodistribution of conventional chemotherapeutics to the tumor site. Also, nanoparticles loaded with chemotherapeutic drugs have the ability to overcome drug resistance which is a major obstacle impeding the progress of the treatment. Multifunctional nanoparticles, which have the potential to further augment the bioavailability of drugs, are being actively investigated. In this review, we will discuss the application of nanoparticles for improving the treatment of sarcoma patients. Springer Science+Business Media, LLC, 2010 nanoparticle nationallicence sarcoma nationallicence tyrosine kinase nationallicence drug resistance nationallicence cancer-initiating cell nationallicence Susa Michiro Department of Orthopaedic Surgery, Massachusetts General Hospital, 02114, Boston, Massachusetts, USA aut Milane Lara Department of Pharmaceutical Sciences, School of Pharmacy, Northeastern University, 02115, Boston, Massachusetts, USA aut Amiji Mansoor Department of Pharmaceutical Sciences, School of Pharmacy, Northeastern University, 02115, Boston, Massachusetts, USA aut Hornicek Francis Department of Orthopaedic Surgery, Massachusetts General Hospital, 02114, Boston, Massachusetts, USA aut Duan Zhenfeng Department of Orthopaedic Surgery, Massachusetts General Hospital, 02114, Boston, Massachusetts, USA aut Pharmaceutical Research Springer US; http://www.springer-ny.com 28/2(2011-02-01), 260-272 0724-8741 28:2<260 2011 28 11095 https://doi.org/10.1007/s11095-010-0173-z text/html Onlinezugriff via DOI 1 review-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s11095-010-0173-z text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Susa Michiro Department of Orthopaedic Surgery, Massachusetts General Hospital, 02114, Boston, Massachusetts, USA aut NATIONALLICENCE 700 1- Milane Lara Department of Pharmaceutical Sciences, School of Pharmacy, Northeastern University, 02115, Boston, Massachusetts, USA aut NATIONALLICENCE 700 1- Amiji Mansoor Department of Pharmaceutical Sciences, School of Pharmacy, Northeastern University, 02115, Boston, Massachusetts, USA aut NATIONALLICENCE 700 1- Hornicek Francis Department of Orthopaedic Surgery, Massachusetts General Hospital, 02114, Boston, Massachusetts, USA aut NATIONALLICENCE 700 1- Duan Zhenfeng Department of Orthopaedic Surgery, Massachusetts General Hospital, 02114, Boston, Massachusetts, USA aut NATIONALLICENCE 773 0- Pharmaceutical Research Springer US; http://www.springer-ny.com 28/2(2011-02-01), 260-272 0724-8741 28:2<260 2011 28 11095 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer